MSD Chief Wants Japan to Eliminate Disincentives Tied to Re-Pricing Rules as Keytruda Faces Repeated Cuts

MSD Japan President Kyle Tattle (right), Japan Development Chief Hiromichi Shirasawa With US Merck seeing its I/O behemoth Keytruda (pembrolizumab) hit by repeated price cuts in Japan, the company's country helmsman Kyle Tattle is urging the government to eliminate massive...read more